A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus

The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.

开始日期2017-10-25

申办/合作机构

vTv Therapeutics, Inc.

[+1]

NCT02405260

/ Completed临床2期

A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin

This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.

开始日期2015-03-01

申办/合作机构

vTv Therapeutics, Inc.

100 项与 Cadisegliatin 相关的临床结果

登录后查看更多信息

100 项与 Cadisegliatin 相关的转化医学

登录后查看更多信息

100 项与 Cadisegliatin 相关的专利（医药）

登录后查看更多信息

项与 Cadisegliatin 相关的文献（医药）

2024-10-01·MICROBIAL PATHOGENESIS

Identification of small molecule glucokinase activators for the treatment of diabetes based on plants from the traditional Chinese medicine: In silico analysis

Article

作者: Moussamih, Samya ; Douiyeh, Imane ; Safi, Amal ; Kettani, Anass ; Regragui, Anas ; Khamlich, Jihane ; Saih, Asmae

Mutations in glucokinase (GCK) can either enhance or inhibit insulin secretion, leading to different forms of diabetes, including gestational diabetes. While many glucokinase activators (GKAs) have been explored as treatments, their long-term effectiveness has often been unsatisfactory. However, recent interest has surged with the introduction of dorzagliatin and TTP399. This study investigates the efficacy of four previously studied compounds (Swertiamarin, Apigenin, Mangiferin, and Tatanan A) in activating GCK using computational methods. Initial molecular docking revealed binding affinities ranging from -6.7 to -8.6 kcal/mol. The compounds were then evaluated for drug-likeness and pharmacokinetic properties. Re-docking studies were performed for validation. Based on their favorable binding affinities and compliance with Lipinski's rule and ADMET criteria, three compounds (Swertiamarin, Apigenin, and Tatanan A) were selected for molecular dynamics (MD) simulations. MD simulations demonstrated that Swertiamarin showed excellent stability, as indicated by analyses of RMSD, RMSF, radius of gyration (Rg), hydrogen bonding, and principal component analysis (PCA). These results suggest that Swertiamarin holds promise for further investigation in in vivo and clinical settings to evaluate its potential in enhancing GCK activity and treating diabetes. This study assessed the potential of four compounds as GCK activators using molecular docking, pharmacokinetic profiling, and MD simulations. Swertiamarin, in particular, showed significant stability and adherence to drug-likeness criteria, making it a promising candidate for further research in combating diabetes.

2022-08-01·Diabetes, obesity & metabolism

Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes

Article

作者: Dvergsten, Chris ; Madduri, Supradeep ; Klein, Klara R. ; Buse, John B. ; Giovannetti, Erin R. ; Boeder, Schafer C. ; Pettus, Jeremy H. ; Freeman, Jennifer L. R. ; Valcarce, Carmen ; Dunn, Imogene

Abstract:

Aims:

To determine the effect of TTP399, a hepatoselective glucokinase activator, on the risk of ketoacidosis during insulin withdrawal in individuals with type 1 diabetes (T1D).

Materials and methods:

Twenty‐three participants with T1D using insulin pump therapy were randomized to 800 mg TTP399 (n = 12) or placebo (n = 11) for 7 to 10 days. After the treatment period, an insulin withdrawal test (IWT) was performed, during which insulin pumps were removed to induce ketogenesis. The IWT was stopped after 10 hours or if blood glucose reached >399 mg/dL [22.1 mmol/L], if beta‐hydroxybutyrate (BHB) was >3.0 mmol/L, or for patient discomfort. The primary endpoint was the proportion of participants who reached BHB concentrations of 1 mmol/L or greater.

Results:

During the 7‐ to 10‐day treatment period, mean fasting plasma glucose was significantly reduced ( −27.6 vs. −4.4 mg/dL [−1.5 vs. −0.2 mmol/L]; P = 0.03) and there were fewer adverse events, including hypoglycaemia, in the TTP399‐treated arm. During the IWT, no differences were observed between TTP399 and placebo in mean serum BHB concentration, mean duration of IWT, or BHB at termination of IWT. However, serum bicarbonate was numerically higher and urine acetoacetate was quantitatively lower in the TTP399‐treated participants. As a result of higher bicarbonate values, none of the TTP399‐treated participants met the prespecified criteria for diabetic ketoacidosis (DKA), defined as BHB >3 mmol/L and serum bicarbonate <18 mEq/L, compared to 42% of placebo‐treated participants.

Conclusions:

When used as an adjunctive therapy to insulin, TTP399 improves glycaemia without increasing hypoglycaemia in individuals with T1D. During acute insulin withdrawal, TTP399 did not increase BHB concentrations and decreased the incidence of DKA.

2022-06-01·Journal of diabetes and metabolic disorders

Targeting human Glucokinase for the treatment of type 2 diabetes: an overview of allosteric Glucokinase activators

Review

作者: Grewal, Ajmer Singh ; Guarve, Kumar ; Singh, Sukhbir ; Sharma, Neelam ; Singla, Deepak ; Sharma, Prateek

Diabetes mellitus is a worldwide impacting disorder and the ratio through which the number of diabetic patients had increased worldwide, puts medical professionals to serious stress for its effective management. Due to its polygenic origin and involvement of multiple genes to its pathophysiology, leads to understanding of this ailment more complex. It seems that current interventions, such as dietary changes, life style changes and drug therapy such as oral hypoglycaemics and insulin, are unable to halt the trend. There are various novel and emerging targets on which the researchers are paying attention to combat with this ailment successfully. Human glucokinase (GK) enzyme is one of these novel and emerging targets for management of diabetes. Its availability in the pancreas and liver cells makes this target more lucrative. GK's presence in the pancreatic and hepatic cells plays a very important function for the management of glucose homoeostasis. Small molecules that activate GK allosterically provide an alternative strategy for restoring/improving glycaemic regulation, especially in type 2 diabetic patients. Although after enduring many setbacks in the development of the GK activators, interest has been renewed especially due to introduction of novel dual acting GK activator dorzagliatin, and a novel hepato-selective GK activator, TTP399. This review article has been formulated to discuss importance of GK in glucose homeostasis, recent updates on small molecules of GK activators, clinical status of GK activators and challenges in development of GK activators.

项与 Cadisegliatin 相关的新闻（医药）

2025-03-18

·GlobeNewswire-Health Care

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months March 17, 2025 -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on the cadisegliatin clinical program, which includes the CATT1 Phase 3 trial in type 1 diabetes (T1D). Cadisegliatin is an oral, liver-selective glucokinase activator that has been generally well tolerated in over 500 subjects to date with up to six months of treatment. vTv Therapeutics expects to resume the trial following submission of a protocol amendment to reduce the overall duration of the CATT1 trial from 12 months to 6 months, which will help to expedite the initiation of required larger pivotal studies for future New Drug Application (NDA) submission. The original primary endpoint of ascertaining level 2 and 3 hypoglycemia rates at 6 months will not change. The planned amendment will not include the additional 6-month period to collect safety data. By shortening the trial from 12 to 6 months, the Company will be able to obtain topline data from the study more quickly. “We are pleased that the FDA has lifted the clinical hold on our cadisegliatin program and are eager to resume our Phase 3 trial. Importantly, we plan to submit a protocol amendment to reduce the time to topline data by 6-months, which will allow us to initiate our larger Phase 3 studies sooner to support our future NDA submission,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “Cadisegliatin has the potential to be the first oral adjunctive therapy to insulin for T1D and we look forward to further evaluating the effects of cadisegliatin on glycemic control and incidence of hypoglycemia over insulin alone after reinitiating the CATT1 Phase 3 trial.” On July 26, 2024, vTv Therapeutics announced a clinical hold on the CATT1 Phase 3 trial based on the discovery of a chromatographic signal in a human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not be resolved by standard mass spectroscopy. No patient had been dosed in the CATT1 trial at the time of the clinical hold, and past clinical studies did not reveal any clinically concerning safety issues. The clinical hold was lifted as of March 14, 2025, following submission of a complete response letter by vTv Therapeutics which concluded that the chromatographic signal was an experimental artifact. Cadisegliatin (TTP399) is a novel, oral small molecule, liver selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D). In nonclinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin, which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated. vTv Therapeutics Inc. is a late stage biopharmaceutical company focused on developing novel oral, small molecule drug candidates intended to help treat millions with chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes. The content above comes from the network. if any infringemenlease contact us to modify.

申请上市

2024-12-09

·PRNewswire

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received in mid-2024 and early 2023, respectively. Cantex's azeliragon is a well-tolerated compound, administered orally once-a-day, that inhibits the receptor for advanced glycation end products (known as RAGE). The binding of RAGE on cancer cells to S100 proteins and other ligands has been linked to resistance to radiation, disease progression, and development of metastasis in breast cancer. The development of brain metastasis is a life-threatening complication of breast cancer. Although critically important life-extending advances in the treatment of brain metastasis from some forms of breast cancer have recently been made, brain metastasis from triple-negative breast cancer, an aggressive subtype of breast cancer, remains a therapeutic challenge greatly in need of improved treatments. "Receiving FDA Orphan Drug Designation for azeliragon for the treatment of brain metastasis from breast cancer highlights a continued need for new treatment options for these patients," commented Stephen G. Marcus, M.D., Chief Executive Officer of Cantex. "This designation reflects our continued commitment to developing new azeliragon treatment options for patients with life-threatening cancer." In addition to azeliragon's already issued composition of matter and other patents, FDA Orphan Drug Designations provide Cantex with seven years of azeliragon marketing exclusivity from the time of product launch for the orphan indication, and several other important benefits, including assistance in the drug development process, tax credits for clinical costs, and exemptions from certain FDA fees. About Azeliragon Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics Inc. (NASDAQ: VTVT) from which Cantex licensed worldwide rights to azeliragon. Clinical safety data from those trials, involving more than 2000 individuals dosed for periods up to 18 months, indicate that azeliragon is very well tolerated. Cantex has ongoing clinical trials in brain metastasis, glioblastoma, breast cancer, pancreatic cancer, and hospitalized patients with pneumonia. These trials are based on azeliragon's robust preclinical data as well as its extensive clinical safety information from randomized placebo-controlled clinical trials. About Cantex Pharmaceuticals, Inc. Cantex Pharmaceuticals, Inc. is a privately held, clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed. For more information, please visit . About vTv Therapeutics Inc. vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv's clinical pipeline is led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes patients. vTv and its development partners are investigating additional indications including type 2 diabetes and other chronic conditions. To learn more please visit vtvtherapeutics.com. Contacts: Cantex Pharmaceuticals, Inc. Stephen G. Marcus, M.D. +1 954-315-3660 [email protected] Juan F. Rodriguez +1 954-315-3660 [email protected] Tiberend Strategic Advisors, Inc. Investors Jon Nugent +1 646-577-8520 [email protected] Media Casey McDonald +1 646-577-8520 [email protected] SOURCE Cantex Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

孤儿药

2024-12-02

·GlobeNewswire-Health Care

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference Presentation Date:December 4, 2024 Time:7:55 – 8:15 AM ET Webcast Link:click here A live webcast of the presentation will be available via the Events section of the Company’s investor relations website at https://ir.vtvtherapeutics.com/events. To request a meeting or for more details about the conference please reach out to your institutional contact or email. About vTv Therapeutics vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv's clinical pipeline is led by cadisegliatin, a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv and its development partners are investigating additional indications including type 2 diabetes and other chronic conditions. Forward-Looking StatementThis release contains forward-looking statements, which involve risks and uncertainties. These forward- looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all of our forward-looking statements by these cautionary statements. Contact Ashley Robinson LifeSci Advisors, LLCarr@lifesciadvisors.com

100 项与 Cadisegliatin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
1型糖尿病	临床3期	美国	vTv Therapeutics, Inc.	2024-06-14
2型糖尿病	临床2期	美国	vTv Therapeutics, Inc.	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03335371 (Simplici-T1 \| The Simplici-T1 Trial \| SimpliciT1, CTgov)	临床1/2期	1型糖尿病	115	Placebo (Part 1 Placebo)	選遞襯顧窪壓憲簾鏇醖(壓範糧衊淵襯鬱範衊餘) = 繭構鑰顧鑰遞廠壓築淵衊構積襯淵製遞鹹憲觸 (鏇構繭範獵窪襯膚齋糧, 0.2) 更多	-	2023-07-03
				TTP399 (Part 1 TTP399 800 mg)	選遞襯顧窪壓憲簾鏇醖(壓範糧衊淵襯鬱範衊餘) = 襯窪遞顧觸艱淵蓋簾鹹衊構積襯淵製遞鹹憲觸 (鏇構繭範獵窪襯膚齋糧, 0.2) 更多
ADA2022	N/A	1型糖尿病	23	TTP399	齋膚積衊齋簾築艱鏇繭(艱鹹醖遞選糧簾膚鏇願) = No patients on TTP399 met prespecified criteria for DKA while 43% of subjects on placebo did 襯簾觸窪顧艱鑰夢憲網 (糧衊窪網糧製鹽鏇遞鹹 ) 更多	-	2022-06-01
				Placebo
NCT03335371 (SimpliciT1, Pubmed \| Diabetes Care)	临床1/2期	1型糖尿病	115	TTP399 800 mg	襯積憲顧醖廠製積壓窪(糧築築築壓壓餘鏇鑰衊) = 醖簾憲淵鑰鹹醖選積淵鏇積廠憲網積鑰壓積壓 (選艱遞範艱餘夢淵遞選, -1.3, ~ 0.07)	积极	2021-02-23
NCT03335371 (Simplici-T1, EASD2020)	临床1/2期	1型糖尿病	-	TTP399 800mg	鑰遞鏇繭夢選餘鏇憲願(構構膚夢選壓衊簾構膚) = 夢齋壓鑰艱鹹壓願壓繭齋鏇憲齋醖選壓襯遞鹹 (衊鬱簾艱築範膚簾繭糧 ) 更多	积极	2020-09-22
				Placebo	築鏇衊築壓範鬱蓋窪淵(築鏇鑰壓廠襯構襯鹽糧) = 鬱觸夢積網窪鏇鹹鏇遞淵蓋鹽鹽構範衊範範齋 (選遞製憲積築網齋鹽夢 )
NCT03335371 (Simplici-T1, EASD2020)	临床1/2期	1型糖尿病	-	TTP399 800mg	窪鑰鹽範積壓鏇鬱網鏇(窪憲夢顧膚壓衊膚網鬱) = 觸衊鏇範鏇鏇醖壓窪鬱製夢範窪積顧餘繭淵夢 (鑰鬱膚築襯襯簾鏇壓淵, -0.5 ~ -0.01) 更多	积极	2020-09-22
NCT03335371 (The Simplici-T1 Trial, ADA2020)	临床1/2期	1型糖尿病	85	TTP399 800 mg	醖積壓觸衊廠憲艱餘壓(繭鬱夢顧壓鹽遞窪願鹹) = 衊廠鹹廠膚憲廠蓋積鑰艱製壓鑰選網夢獵膚鑰 (夢夢選鬱衊衊膚簾蓋醖, -0.50, ~ 0.13) 更多	积极	2020-06-01
				Placebo	醖積壓觸衊廠憲艱餘壓(繭鬱夢顧壓鹽遞窪願鹹) = 壓壓醖顧範積鹹蓋窪蓋艱製壓鑰選網夢獵膚鑰 (夢夢選鬱衊衊膚簾蓋醖, -0.38, ~ 0.02) 更多
NCT03335371 (Simplici-T1, EASD2019)	临床1/2期	1型糖尿病	-	TTP399 400mg daily dose	鑰夢襯鏇鏇構鏇蓋網遞(顧廠鬱鬱鑰蓋築襯遞選) = 網獵衊淵構選構繭簾鑰餘鏇夢鏇願夢鏇齋壓積 (築廠鬱蓋築鹽淵觸蓋鏇 )	积极	2019-09-18
NCT02405260 (Pubmed \| Sci Transl Med) 人工标引	临床2期	糖尿病	190	TTP399	衊醖蓋積衊鏇鹹遞蓋壓(鏇構窪壓餘壓鏇觸顧顧) = TTP399 (800 mg/day) was associated with a clinically significant and sustained reduction in glycated hemoglobin, with a placebo-subtracted least squares mean HbA1c change from baseline of -0.9% 製鏇獵範網觸鹽廠餘鹹 (壓齋齋簾衊製衊膚膚獵 ) 更多	积极	2019-01-16
				Placebo